Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABER: Bioequivalence of Sublingual vs Intramuscular Atropine Sulfate
NCT06366087Phase 1Completed
- Sponsor
- Biomedical Advanced Research and Development Authority
- Start
- Apr 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Myopine in bradycardia and Muscarinic Poisoning (2 arms), sponsored by Biomedical Advanced Research and Development Authority. Primary endpoints: Area Under the Analyte Concentration Versus Time Curve to Infinity at 8 hours and Area Under the Analyte Concentration Versus Time Curve to Time of Last Quantifiable Data Point at 8 hours. Started Apr 2024; status: completed.
02
Drugs
Myopine
03
Conditions
bradycardiaMuscarinic Poisoning
Beyond the preview
Go deeper on NCT06366087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06366087.